Efficacy and Safety of Duloxetine on Osteoarthritis Knee Pain: A Meta-Analysis of Randomized Controlled Trials

Pain Medicine (United States)

Volumn 16, Issue 7, 2015, Pages 1373-1385

  Wang, Zhao Yu ^a   Shi, Sheng Ying ^b   Li, Shu Jie ^b   Chen, Feng ^c   Chen, Huang ^a   Lin, Hai Zhen ^b   Lin, Jing Ming ^b  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c SHANTOU UNIVERSITY   (China)

Author keywords

Duloxetine; Meta Analysis; Osteoarthritis Knee Pain; Randomized Controlled Trials

Indexed keywords

DULOXETINE; PLACEBO; ANALGESIC AGENT;

ADULT; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CONSTIPATION; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION AND FOLLOW UP; FATIGUE; FEMALE; HUMAN; INSOMNIA; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; NAUSEA; OUTCOME ASSESSMENT; PAIN INTENSITY; PAIN SEVERITY; PATIENT GLOBAL IMPRESSION OF IMPROVEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; XEROSTOMIA; DOSE RESPONSE; DRUG EFFECTS; KNEE; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

ANALGESICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DULOXETINE HYDROCHLORIDE; HUMANS; KNEE JOINT; OSTEOARTHRITIS, KNEE; PAIN MANAGEMENT; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84948163376     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12800     Document Type: Article

References (52)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Skevington SM. Investigating the relationship between pain and discomfort and quality of life, using the WHO-QOL. Pain 1998;76:395-406.
3. Axford J, Heron C, Ross F, Victor CR. Management of knee osteoarthritis inprimary care: Pain and depression are the major obstacles. J Psychosom Res 2008;64:461-7.
4. Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med 2008;70:890-7.
5. Centers for Disease Control and Prevention (CDC) . Prevalence of disabilities and associated health conditions among adults-United States, 1999. MMWR Morb Mortal Wkly Rep 2001;50:120-25.
6. Quintana JM, Arostegui I, Escobar A, et al. Prevalence of knee and hip osteoarthritis and the appropriateness of joint replacement in an older population. Arch Intern Med 2008;168:1576-84.
7. Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum 2008;59:1207-13.
8. Creamer P. Osteoarthritis pain and its treatment. Curr Opin Rheumatol 2000;12:450-5.
9. Felson DT, Lawrence RC, Hochberg MC, et al. Osteoarthritis: New insights. Part 2: Treatment approaches. Ann Intern Med 2000;133:726-37.
10. KI˙RAZLI Y. Current approach to the guidelines for the diagnosis and treatment of osteoarthritis. Turk JGeriatr-Turk GeriatrI Dergisi. 2011;14:119-25.
11. Conaghan PG, Dickson J, Grant RL. Guidelines: Care and management of osteoarthritis in adults: Summary of NICE guidance. BMJ 2008;336:502
12. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62.
13. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15.
14. Hochberg MC, Dougados M. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol 2001;15:583-93.
15. Fitzcharles MA, Lussier D, Shir Y. Management of chronic arthritis pain in the elderly. Drugs & Aging 2010;27:471-90.
16. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991;14:219-45.
17. Jones CK, Peters SC, Shannon HE. Efficacyof duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 2005;312:726-32.
18. Bajaj P, Bajaj P, Graven-Nielsen T, Arendt-Nielsen L. Osteoarthritis and its association with muscle hyperalgesia: An experimental controlled study. Pain 2001;93:107-14.
19. Kidd BL. Osteoarthritis and joint pain. Pain 2006;123:6-9.
20. Iyengar S, Webster AA, Henrick-Lucke SK, Xu JY, Simmons RMA. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576-84.
21. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants-potential for greater efficacy or just hype? in progress in drug research. Birkhäuser Basel 2002;169-222.
22. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56.
23. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20.
24. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84.
25. Russell JI, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44.
26. Skljarevski V, Ossanna MJ, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009;16:1041-8.
27. Skljarevski V, Zhang S, Desaiah D, et al. PatrickK: Duloxetine versus placebo in patients with chronic low back pain: A12-week, fixed dose, randomized, double-blind trial. J Pain 2010;11:1282-90.
28. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial. Pain 2009;146:253-60.
29. ClinicalTrials.gov. Duloxetine Versus Placebo for Osteoarthritis Knee Pain. Eli Lilly and Co. Updated July 7, 2009. Available at: http://clinicaltrials.gov/ct2/show/NCT00408421 (accessed August 30, 2011).
30. Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11:33-41.
31. ClinicalTrials.gov. Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain. Eli Lilly and Co. Updated August 26, 2009. Available at: http://clinicaltrials.gov/ct2/show/NCT00433290 (accessed August 30, 2011).
32. Frakes EP, Risser RC, Ball TD, et al. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: Results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:2361-72.
33. ClinicalTrials.gov. A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis. Eli Lilly and Co. Updated April 28, 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT01018680 (accessed August 30, 2011).
34. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update//mayo clinic proceedings. Elsevier 2010;85:S3-14.
35. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 1996;17:1-12.
36. J. P. T. Higgins, S. Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. Oxford: The Cochrane Collaboration, 2008. www.cochrane-handbook.org.
37. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol 2001;54:1046-55.
38. Brown JP, Boulay LJ. Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee. Ther Adv Musculoskelet Dis 2013;5:291-304.
39. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
40. Risser RC, Hochberg MC, Gaynor PJ, D'Souza DN, Frakes EP. Responsiveness of the intermittent and constant osteoarthritis pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain. Osteoarthritis Cartilage 2013;21:691-94.
41. Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: Randomised placebo-controlled trial. Age Ageing 2012;41:646-52.
42. Micca JL, Ruff D, Ahl J, Wohlreich MM. Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: A post hoc, subgroup analysis of two randomized, placebo-controlled trials. BMC Musculoskelet Disord 2013;14:137
43. Hochberg MC, Wohlreich M, Gaynor P, Hanna S, Risser R. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol 2012;39:352-58.
44. Cleeland CS, Ryan KM. Pain assessment: Global use of the brief pain inventory. Ann Acad Med Singapore 1994;23:129-38.
45. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health; 1976. DHEW Pub. No. ADM, 76-338.
46. Benn S. and, Woolf C. Adult neuron survival strategies-slamming on the brakes. Nat Rev Neurosci 2004;5:686-700.
47. Goldstein DJ, Lu Y, Detke MJ, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17-28.
48. Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: An analgesic or antidepressant effect? Int Clin Psychopharmacol 2006;21:311-17.
49. Russell JM, Weisberg R, Fava M, et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2008;25:E1-11.
50. Higgins J, Thompson S, Deeks J, et al. Statistical heterogeneity in systematic reviews of clinical trials: A critical appraisal of guidelines and practice. J Health Serv Res Policy 2002;7:51-61.
51. Lau J, Ioannidis JPA, Schmid CH. Summing up the evidence: One answer is not always enough. Lancet 1997;351:123-7.
52. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or i2 index? Psychol Methods, 2006;11:193